C
AVIR icon

Covestor’s Atea Pharmaceuticals AVIR Stock Holding History

Covestor’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-93
Closed – – 2260
2025
Q3 		$0 Buy
93
+8
+9% +$27 ﹤0.01% 2279
2025
Q2 		$0 Buy
85
+3
+4% +$9 ﹤0.01% 2199
2025
Q1 		$0 Buy
82
+15
+22% +$47 ﹤0.01% 2207
2024
Q4 		$0 Buy
67
+1
+2% +$3 ﹤0.01% 2223
2024
Q3 		$0 Sell
66
-52
-44% -$189 ﹤0.01% 2206
2024
Q2 		$0 Buy
+118
New +$440 ﹤0.01% 2232
2023
Q3 		– Sell
-83
Closed – – 2104
2023
Q2 		$0 Sell
83
-929
-92% -$3.48K ﹤0.01% 2121
2023
Q1 		$3K Buy
+1,012
New +$4.11K ﹤0.01% 1651
2022
Q1 		– Sell
-40
Closed – – 2093
2021
Q4 		$0 Buy
+40
New +$623 ﹤0.01% 2104

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Covestor's AVIR Position: Q4 2025 in Review

Covestor sold out of Atea Pharmaceuticals (AVIR) in Q4 2025, closing a stake of 93 shares.

Covestor first reported a position in AVIR in Q4 2021 and held it in 9 quarters. The position peaked at $3K in Q1 2023. 111 funds tracked by Wall St. Rank hold AVIR as of Q4 2025.

  • Covestor reported no remaining Atea Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Covestor sold 93 Atea Pharmaceuticals shares in Q4 2025.
  • Covestor first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • Covestor's Atea Pharmaceuticals position peaked at $3K in Q1 2023.
  • 111 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2025.

Based on Covestor's 13F filing for Q4 2025, filed 6 Feb 2026.